Genetic Technologies Valuation
| GENE Stock | USD 0.77 0.00 0.00% |
Genetic Technologies is overvalued. Genetic Technologies retains a regular Real Value of $0.67 per share. The prevalent price of the firm is $0.77. Our model calculates the value of Genetic Technologies from evaluating the firm fundamentals such as Current Valuation of 3.6 M, return on equity of -1.85, and Return On Asset of -0.63 as well as inspecting its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Genetic Technologies' valuation include:
Price Book 3.1122 | Enterprise Value 3.6 M | Enterprise Value Ebitda (2.44) | Price Sales 0.3834 | Enterprise Value Revenue 0.07 |
Overvalued
Today
Please note that Genetic Technologies' price fluctuation is dangerous at this time. Calculation of the real value of Genetic Technologies is based on 3 months time horizon. Increasing Genetic Technologies' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Genetic stock is determined by what a typical buyer is willing to pay for full or partial control of Genetic Technologies. Since Genetic Technologies is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Genetic Stock. However, Genetic Technologies' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.77 | Real 0.67 | Hype 0.78 | Naive 0.78 |
The real value of Genetic Stock, also known as its intrinsic value, is the underlying worth of Genetic Technologies Company, which is reflected in its stock price. It is based on Genetic Technologies' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Genetic Technologies' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Genetic Technologies helps investors to forecast how Genetic stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Genetic Technologies more accurately as focusing exclusively on Genetic Technologies' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Genetic Technologies' intrinsic value based on its ongoing forecasts of Genetic Technologies' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Genetic Technologies' closest peers. If more than one evaluation category is relevant for Genetic Technologies we suggest using both methods to arrive at a better estimate.
Genetic Technologies Cash |
|
Genetic Valuation Trend
Comparing Genetic Technologies' enterprise value against its market capitalization is a good way to estimate the value of Genetic Technologies uage its performance over time. This information may sometimes be enough for investors to make reasonable market timing decisions.
Genetic Technologies Total Value Analysis
Genetic Technologies is currently estimated to have valuation of 3.6 M with market capitalization of 3.71 M, debt of 875.19 K, and cash on hands of 11.74 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Genetic Technologies fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
3.6 M | 3.71 M | 875.19 K | 11.74 M |
Genetic Technologies Investor Information
The book value of the company was currently reported as 0.01. The company recorded a loss per share of 0.02. Genetic Technologies last dividend was issued on the 15th of August 2019. The entity had 1:5 split on the 14th of December 2023. Based on the key indicators related to Genetic Technologies' liquidity, profitability, solvency, and operating efficiency, Genetic Technologies is not in a good financial situation at this time. It has a very high probability of going through financial hardship in December.Genetic Technologies Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Genetic Technologies has an asset utilization ratio of 123.89 percent. This indicates that the Company is making $1.24 for each dollar of assets. An increasing asset utilization means that Genetic Technologies is more efficient with each dollar of assets it utilizes for everyday operations.Genetic Technologies Ownership Allocation
Roughly 98.9 (percent) of Genetic Technologies outstanding shares are held by general public with 1.1 pct. by outside corporations.Genetic Technologies Profitability Analysis
The company reported the previous year's revenue of 7.66 M. Net Loss for the year was (12.02 M) with profit before overhead, payroll, taxes, and interest of 6.01 M.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Genetic Technologies' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Genetic Technologies and how it compares across the competition.
About Genetic Technologies Valuation
The stock valuation mechanism determines Genetic Technologies' current worth on a weekly basis. Our valuation model uses a comparative analysis of Genetic Technologies. We calculate exposure to Genetic Technologies's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Genetic Technologies's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 3.9 M | 3.8 M | |
| Pretax Profit Margin | (1.57) | (1.65) | |
| Operating Profit Margin | (0.85) | (0.90) | |
| Net Loss | (1.57) | (1.65) | |
| Gross Profit Margin | 0.51 | 0.53 |
Genetic Technologies Growth Indicators
Investing in growth stocks can be very risky. If the company such as Genetic Technologies does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 132.2 M |
Genetic Technologies Current Valuation Indicators
Valuation refers to the process of determining the present value of Genetic Technologies and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Genetic we look at many different elements of the entity such as Genetic's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Genetic Technologies, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Genetic Technologies' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Genetic Technologies' worth.Complementary Tools for Genetic Stock analysis
When running Genetic Technologies' price analysis, check to measure Genetic Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genetic Technologies is operating at the current time. Most of Genetic Technologies' value examination focuses on studying past and present price action to predict the probability of Genetic Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genetic Technologies' price. Additionally, you may evaluate how the addition of Genetic Technologies to your portfolios can decrease your overall portfolio volatility.
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |